These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24583)

  • 1. Modification of the immunologic properties of the cell surface.
    Hakim AA
    Immunol Commun; 1978; 7(1):25-39. PubMed ID: 24583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzymically-mediated changes in murine mammary adenocarcinoma cell membrane induces changes in lymphoid tissue immune ribonucleic acids.
    Hakim AA
    Arch Geschwulstforsch; 1980; 50(7):613-27. PubMed ID: 6165333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenicity of a spontaneous murine mammary adenocarcinoma during in vitro cultivation.
    Hakim AA
    Tumori; 1977; 63(5):415-27. PubMed ID: 23597
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor therapy of neoplastic diseases with tumor cells and neuraminidase: experimental studies on chessboard vaccination in transplantation tumors.
    Sedlacek HH; Bengelsdorff KH; Hagmayer G; Seiler FR
    Int J Immunopharmacol; 1987; 9(7):841-50. PubMed ID: 3429076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental cancer immunotherapy: modification of tumor cells to increase immunogenicity.
    Rios A; Simmons RL
    Ann N Y Acad Sci; 1976; 276():45-60. PubMed ID: 68699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of fixed antigenic, non-oncogenic and protective neoplastic cells.
    Hakim AA
    Experientia; 1977 Apr; 33(4):518-20. PubMed ID: 862758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell surface modification in the treatment of experimental cancer: neuraminidase or concanavalin A.
    Simmons RL; Rios A
    Cancer; 1974 Oct; 34(4 Suppl):suppl:1541-7. PubMed ID: 4138077
    [No Abstract]   [Full Text] [Related]  

  • 8. Differential effect of neuraminidase on the immunogenicity of viral associated and private antigens of mammary carcinomas.
    Simmons RL; Rios A
    J Immunol; 1973 Dec; 111(6):1820-5. PubMed ID: 4750868
    [No Abstract]   [Full Text] [Related]  

  • 9. Characteristics of immunity induced by neuraminidase-treated lymphosarcoma cells in C3H (MTV+) and C3H (MTV-) mice.
    Bekesi JG; Roboz JP; Holland JF
    Isr J Med Sci; 1976; 12(4-5):288-303. PubMed ID: 181351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serologically defined, unique surface antigen on a mouse mammary adenocarcinoma.
    Kuzumaki N; Klein G
    J Natl Cancer Inst; 1979 Mar; 62(3):619-22. PubMed ID: 84092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effectiveness of neuraminidase-treated tumor cells as an immunogen in man and experimental animals with leukemia.
    Bekesi JG; Roboz JP; Holland JF
    Ann N Y Acad Sci; 1976; 277(00):313-31. PubMed ID: 1069551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological analysis of A strain mice bearing the A-10 mammary adenocarcinoma.
    Tax A; Manson LA
    Cancer Res; 1979 May; 39(5):1739-47. PubMed ID: 85488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active specific immunotherapy of minimal residual tumor: excision plus neuraminidase-treated tumor cells.
    Rios A; Simmons RL
    Int J Cancer; 1974 Jan; 13(1):71-81. PubMed ID: 4818273
    [No Abstract]   [Full Text] [Related]  

  • 14. Monoclonal antibody against a cryptic carbohydrate antigen of murine and human lymphocytes. I. Antigen expression in non-cryptic or unsubstituted form on certain murine lymphomas, on a spontaneous murine mammary carcinoma, and on several human adenocarcinomas.
    Longenecker BM; Rahman AF; Leigh JB; Purser RA; Greenberg AH; Willans DJ; Keller O; Petrik PK; Thay TY; Suresh MR
    Int J Cancer; 1984 Jan; 33(1):123-9. PubMed ID: 6198295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor therapy of neoplastic diseases with tumor cells and neuraminidase. Further experimental studies on chessboard vaccination in canine mammary tumors.
    Sedlacek HH; Hagmayer G; Seiler FR
    Cancer Immunol Immunother; 1986; 23(3):192-9. PubMed ID: 3791304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuraminidase treated cells and their role in cancer immunotherapy.
    Simmons RL; Rios A
    Birth Defects Orig Artic Ser; 1973 Mar; 9(2):223-8. PubMed ID: 4611534
    [No Abstract]   [Full Text] [Related]  

  • 17. Immune response to inactivated syngeneic mammary adenocarcinoma cells. I. Role and regulation of antibody synthesis in DBA/2 mice.
    DeLustro F; Haskill JS
    J Natl Cancer Inst; 1980 Jan; 64(1):125-30. PubMed ID: 6928037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of spontaneous mammary carcinomas using direct injections of neuraminidase and BCG.
    Simmons RL; Rios A; Kersey JH
    J Surg Res; 1972 Feb; 12(2):57-61. PubMed ID: 4111004
    [No Abstract]   [Full Text] [Related]  

  • 19. Micro-necrotic foci in regression of a murine calvarium transplantable tumor. 2. Enzymatic modification of the transformed calvarium cell immunological characteristics.
    Hakim AA
    Neoplasma; 1980; 27(4):449-58. PubMed ID: 7453860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal histamine metabolism in a transplantable syngeneic spontaneous murine mammary adenocarcinoma.
    Scolnik AJ; Rubio MC; Comolli RR; Colombo LL; Caro RA
    Biomedicine; 1981 Jul; 35(3):84-7. PubMed ID: 7272425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.